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ABSTRACT
Mucins are high molecular weight O-glycoproteins that are predominantly
expressed at the apical surface of epithelial cells and have wide range of functions.
The functional diversity is attributed to their structure that comprises of a peptide
chain with unique domains and multiple carbohydrate moieties added during
SRVWWUDQVODWLRQDOPRGL¿FDWLRQV7XPRUFHOOVDEHUUDQWO\RYHUH[SUHVVPXFLQVDQG
thereby promote proliferation, differentiation, motility, invasion and metastasis.
Along with their aberrant expression, accumulating evidence suggest the critical
role of altered subcellular localization of mucins under pathological conditions due
to altered endocytic processes. The mislocalization of mucins and their interactions
UHVXOWLQFKDQJHLQWKHGHQVLW\DQGDFWLYLW\RILPSRUWDQWFHOOPHPEUDQHSURWHLQV OLNH
UHFHSWRUW\URVLQHNLQDVHV WRIDFLOLWDWHYDULRXVVLJQDOLQJZKLFKKHOSFDQFHUFHOOV
to proliferate, survive and progress to more aggressive phenotype. In this review
DUWLFOHZHVXPPDUL]HVWXGLHVRQPXFLQVWUDI¿FNLQJDQGSURYLGHDSHUVSHFWLYHRQLWV
importance to pathological conditions and to answer critical questions including its
use for therapeutic interventions.

breast, gastric and ovarian cancer [7-9], and its overexpression
has been associated with the poor prognosis of pancreatic
cancer and cholangiocarcinoma [10, 11]. However, MUC4
expression is down-regulated during prostate carcinomas
[12] and urothelial cancer [13], suggesting the complicated
context-dependent role of mucins. Another example, MUC1
LVRYHUH[SUHVVHGLQYDULRXVPDOLJQDQFLHVDQGLQÀDPPDWRU\
conditions [1, 14-16]. Besides the aberrant overexpression
of MUC, emerging evidence suggests that anomalies in
their subcellular localization and resultant changes in their
HQGRF\WLFWUDI¿FNLQJSOD\FULWLFDOUROHVXQGHUSDWKRORJLFDO
conditions [17].
In a cell, majority of proteins are not pre-set to any
single location and are in a steady-state distribution due to
opposing egress (exocytosis) and entrance (endocytosis)

INTRODUCTION
Mucins (MUC) are high molecular weight
O-glycoproteins, predominantly expressed at the apical
VXUIDFH RI WKH HSLWKHOLDO FHOOV >@ 7LVVXH VSHFL¿F
expressions of MUC have essential functions to provide
protection, lubrication to epithelial cells, maintenance of
epithelial characteristics, cellular adhesion, differentiation,
DQGLPPXQLW\>@7KHH[SUHVVLRQRI08&LVVLJQL¿FDQWO\
altered during tumorigenesis and other pathological
conditions. For example, MUC4 is not expressed in the
normal pancreas, but the early pancreatic intraepithelial
neoplasia (PanINs) precursor lesions have been shown
to express MUC4, which further increases as the disease
progresses [4-6]. In addition, MUC4 is also overexpressed in
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UHWLFXOXPWR*ROJLFRPSOH[DQG¿QDOO\WRWKHFHOOVXUIDFH
MUC, including MUC1, MUC3, MUC16, and MUC17
DUHFOHDYHGDWWKHLUHYROXWLRQDU\FRQVHUYHG6($GRPDLQ
E\DQXQLGHQWL¿HGLQWUDFHOOXODUSURWHDVHFKDQJHVLQS+
ionic concentrations and mechanical stress [4,23,24].
7KH FOHDYHG H[WUDFHOOXODU GRPDLQV (&'  DUH VKHGGHG
to rapidly clear cell surface associated materials or
colonized/associated pathogens [25,26]. MUC that do not
KDYHWKH6($GRPDLQHJ08&08&08&$&DUH
SRVWXODWHGWRJHWFOHDYHGDWWKHLU*'3+ *O\$VS3UR+LV 
sequence [27-29]. The substitution of the aspartic residue
ZLWKJOXWDPLFUHVLGXHLQWKH*'3+VHTXHQFHZKLFKOHDGV
to the lengthening of the side chain by one carbon, has
shown to abolish the cleavage [29]. Acidic environment
of endoplasmic reticulum plays an important role in
*'3+FOHDYDJHWKRXJKGLIIHUHQW08&UHTXLUHGLIIHUHQW
pH for the cleavage. For example, MUC2 cleavage is
stimulated at pH less than 6 [27], whereas MUC5AC
cleavage has been demonstrated to occur at neutral pH of
endoplasmic reticulum [29]. Nevertheless, the cleavage of
the MUC5AC mucin is augmented at lower pH.
7KH SDWKZD\V RI 08& WUDI¿FNLQJ DUH ODUJHO\
similar for both secretory and membrane bound MUC,
DQGWKHVOLJKWGLIIHUHQFHVLQWKHLUWUDI¿FNLQJRFFXUGXH
to variability in their domains. For instance, dimerization
of MUC2 occurs in the endoplasmic reticulum due
WR IRUPDWLRQ RI GLVXO¿GH ERQGV LQ WKH F\VWHLQH NQRW
domain [30] and the subsequent trimerization occur by
IRUPLQJ GLVXO¿GH ERQGV LQ WKH Y:' GRPDLQ LQ7*1
[31]. MUC2 and possibly other gel forming secretory
08&IRUPODUJHQHWOLNHVWUXFWXUHVUHTXLUHGWRSURWHFW
epithelia from various harsh conditions. The dense
SDFNLQJRI08&LQVHFUHWRU\JUDQXOHVRFFXUVGXHWRWKH
formation of large aggregates under high Ca2+ and low pH
conditions (Fig. 1) [32]. Calcium depletion and HCO3mediated pH neutralization can unfold these aggregates
and tightly clumped MUC. The HCO3- ion transportation
across the plasma membrane occurred by cystic
¿EURVLV WUDQVPHPEUDQH FRQGXFWDQFH UHJXODWRU &)75 
FKDQQHO>@0XWDWLRQLQ&)75FKDQQHOKDVEHHQZHOO
HVWDEOLVKHGZLWKWKHSDWKRJHQHVLVRIF\VWLF¿EURVLVZKLFK
is accompanied with persistently acidic intracellular
pH. It leads to 3–4 fold increase in the secretion of
08& DV WKH SDFNLQJ DQG DJJUHJDWLRQ RI JHOIRUPLQJ
MUC are favored under such acidic condition [33].
Three proteins associated with the secretory MUC
LQFOXGHP\ULVWR\ODWHGDODQLQHULFK&NLQDVHVXEVWUDWH
calcium-activated chloride channel 3, and cysteine string
SURWHLQDQGKHDWVKRFNSURWHLQ +63 7KHVHSURWHLQ
are considered to be highly crucial as their inhibition
DWWHQXDWHV VHFUHWLRQ RI 08& >@ 6\QDSWRWDJPLQV
D IDPLO\ RI ORZ DI¿QLW\ &D2+ sensor proteins, are also
involved in more than 90% of acute MUC secretion upon
extracellular signals [35].

pathways [18]. These two pathways are extremely dynamic
DQGDUHUHJXODWHGE\KLJKO\VHQVLWLYHFURVVWDONVEHWZHHQ
different subcellular compartments. Endocytic pathways
have always been considered as enduring mechanisms
for recycling molecules from the plasma membrane
to different intracellular compartments, and reduce
receptor density at the cell surface resulting in signal
attenuation. Proteins could be endocytosed by utilizing
clathrin-mediated pathway, caveolae-mediated pathway,
macropinocytosis, and phagocytosis [19]. The MUC1
utilizes these pathways for endocytosis and cell surface
localization [20-22] (Fig. 1  /LNH RWKHU JO\FRSURWHLQV
MUC are also sorted after their internalization in the
early or sorting endosome, where their fates are decided
including their recycling, transportation to the Golgi
(retrograde), and proteosomal or lysosomal degradation.
7KLV LV QRW RQO\ UHVSRQVLEOH IRU HI¿FLHQW DQG UHJXODWHG
cellular metabolism and signal transduction, but is
also required for coordinating the functions of each
LQWUDFHOOXODU FRPSDUWPHQW E\ PDLQWDLQLQJ WKHLU VSHFL¿F
FRPSRVLWLRQV ,QWULJXLQJO\ WKH WUDI¿FNLQJ RI 08&
and other glycoproteins is mainly regulated by postWUDQVODWLRQDO PRGL¿FDWLRQV LQFOXGLQJ SKRVSKRU\ODWLRQ
glycosylation, palmitoylation and ubiquitylation.
In this review article, we provide a perspective
RQ 08& WUDI¿FNLQJ DQG LWV SHUWLQHQFH WR SDWKRORJLFDO
conditions and discuss critical issues surrounding its
potential use for therapeutic interventions.

MUC BIOSYNTHESIS AND MECHANISM
OF THEIR SECRETION
08& DUH EURDGO\ FODVVL¿HG LQWR WZR FDWHJRULHV
membrane bound mucins and secretory mucins.
Membrane bound mucins (such as MUC1, MUC3,
MUC4, MUC16, MUC17) have the ability to tether
themselves into the plasma membrane due to the presence
of transmembrane domain, whereas secretory mucins
VXFK DV 08& 08&$& 08&%  JHW SDFNDJHG
into secretory vesicles and released upon receiving
appropriate extracellular signal (Fig. 1) [4]. MUC have
different physicochemical properties due to the presence
RIGLIIHUHQWGRPDLQVOLNHQLGRJHQOLNHGRPDLQ 1,'2 
VHDXUFKLQVSHUPSURWHLQ±HQWHURNLQDVH±DJULQ 6($ YRQ
:LOOHEUDQGIDFWRU'GRPDLQ Y:' DQGHSLGHUPDOJURZWK
IDFWRU (*) OLNHGRPDLQ$OOWKH08&DUHWUDQVODWHGDV
a single polypeptides chain and are processed into rough
endoplasmic reticulum and Golgi complex to acquire
SRVWWUDQVODWLRQDO PRGL¿FDWLRQV SUHGRPLQDWHO\ 1 DQG
2OLQNHGJO\FRV\ODWLRQ
Apart from glycosylation, some MUC are cleaved at
VSHFL¿FSURWHRO\WLFFOHDYDJHVLWHVGXULQJSRVWWUDQVODWLRQDO
processing, which create two subunits that remain
associated throughout their transport from endoplasmic

www.impactjournals.com/oncotarget

7273

Oncotarget

Figure 1: Diagrammatical representation of the intracellular transport of glycoproteins along endocytic and exocytic
pathways. Internalization of cell surface glycoproteins occurs by clathrin-mediated, caveolin-mediated, or clathrin- & caveolinindependent pathways, followed by the fusion of internalized vesicles with early endosomes where the cargo is sorted and targeted for
either recycling (from trans-Golgi, late endosome and recycling endosome) or for degradation (in lysosomes). The other exocytic route
DUHUHSUHVHQWDWLYHRIWKHVHFUHWRU\SDWKZD\VZKHUHJO\FRSURWHLQVDUH¿UVWV\QWKHVL]HGDQGSURFHVVHGLQWKHURXJK(5IROORZHGE\WKHLU
HQWU\LQWRWKH*ROJLZKHUHWKH\DUHIXUWKHUPRGL¿HGSDFNDJHGLQWRVHFUHWRU\YHVLFOHV 69 DQGHLWKHUWDUJHWHGWRWKHSODVPDPHPEUDQHRU
secreted by the exocytic machinery.

Abbreviations: ((HDUO\HQGRVRPH5(UHF\FOLQJHQGRVRPH0%0VPHPEUDQHERXQGPXFLQV60VVHFUHWRU\PXFLQV
69VHFUHWRU\YHVLFOHV6*VHFUHWRU\JUDQXOHV(&H[WUDFHOOXODU
have better prognosis, whereas MUC1 cytoplasmic
localization in tumors correlated with worse prognosis [37].
Aberrant cytoplasmic MUC1 localization has also been
FRUUHODWHGZLWKKLJKULVNSDSLOODU\WK\URLGFDUFLQRPD>@
In breast ductal adenocarcinomas, MUC2 and MUC5AC
are localized in cytoplasm with granular staining pattern
[14, 39, 40], whereas distribution of MUC5B expression
changes from apical localization in non-malignant breast
cells to cytoplasmic and non-apical localization in malignant
GXFWDOEUHDVWFDUFLQRPD>@6LPLODUO\08&FHOOVXUIDFH
expression has been correlated with poor prognosis, higher
JUDGHDQGQHJDWLYH(5H[SUHVVLRQLQEUHDVWFDUFLQRPD>@
These studies clearly demonstrate that, aberrant localization
of MUC is associated with cancer pathology [14, 36, 38, 39],

ALTERED LOCALIZATION OF MUC
Cytoplasmic localization and its association
with disease
In 1992, Ceriani and colleagues conducted immunohistochemistry (IHC) analysis of MUC1 cytoplasmic and
membranous expression/localization on 227 breast cancer
patients. They found that low cytoplasmic intensity and
high cell surface localization of MUC1 correlated with
better prognosis of breast cancer patients and survival
>@7KLVREVHUYDWLRQZDVIXUWKHUYDOLGDWHGE\5DKQet al.,
who found that increased cell surface MUC1 expression
LQORZHUJUDGHDQGHVWURJHQUHFHSWRU (5 SRVLWLYHWXPRUV
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and therefore, it is essential to investigate the mechanisms
WKDWDOWHUWUDI¿FNLQJRI08&DPRQJGLIIHUHQWVXEFHOOXODU
FRPSDUWPHQWV 6R IDU QR GH¿QLWH PHFKDQLVP KDV EHHQ
established to understand the elevated intracellular presence
RI08&LQFDQFHUEXWGLIIHUHQWSRVWXODWLRQVVSHFL¿FDOO\
for MUC1, have been put forth including; its impaired
recycling, altered glycosylation, altered endocytosis and
other presumed changes in MUC dynamics (Fig. 2), which
will be discussed in detail in the next sections.

mammary ductal epithelium (Fig. 2A). The cytoplasmic
domain of MUC1 (or MUC1-C) is comprised of 58
DPLQR DFLGV RI WKH (&'  DPLQR DFLGV RI WKH 70
domain and 72 amino acids of the cytoplasmic tail (CT).
MUC1-C does not contain a prototypical monopartite
QXFOHDU ORFDOL]DWLRQ VLJQDO 1/6  WKRXJK LW KDV D
SRVLWLYHO\ FKDUJHG DPLQR DFLG VWUHWFK NQRZQ DV WKH
55.PRWLIDQGKDVEHHQLPSOLFDWHGLQȖFDWHQLQQXFOHDU
ORFDOL]DWLRQ>@$VLPLODUSRWHQWLDO1/6LVDOVRSUHVHQW
in MUC16-CT, but it is yet to be investigated for its
role in MUC 16-CT nuclear translocation [44]. In breast
cancer cell lines, FGF1 has been found to facilitate the
targeting of MUC1-C to the nucleus [45]. FGF1 induced
the phosphorylation of MUC1 on Tyr46 residue, which

Nuclear translocation of MUC1
5HSRUWV KDYH VKRZQ QXFOHRODU ORFDOL]DWLRQ RI
MUC1 in human breast carcinomas but not in normal

Figure 2: Mechanisms of intracellular transport and sorting of MUC1. MUC1 has demonstrated to be internalization by using
FODWKULQDQGFDYHROLQPHGLDWHGSDWKZD\ZKLFKLVGHSHQGHQWRQ5DEDDQHDUO\HQGRVRPHPDUNHU08&KDVPDQ\LQWHUDFWLQJSDUWQHUV
LQFOXGLQJ(*)5IDPLO\SURWHLQV$3*UEDQGȕFDWHQLQ08&SRVVHVVHVDȖVHFUHWDVHFOHDYDJHVLWHDQGJHWFOHDYHGLQHDUO\HQGRVRPH
(A)&OHDYHG08&&ZKLFKLVVWLOOLQFRQWDFWZLWKȕFDWHQLQWUDYHOVWRQXFOHXVWRLQFUHDVHWKHWUDQVFULSWLRQRIYDULRXVJHQHVWKDWDUH
UHJXODWHGE\WKH7&)SURPRWHU08&&LQWHUDFWVZLWKKHDWVKRFNSURWHLQVIRUPLWRFKRQGULDO(B) and lysosomal (C) translocation resulting
LQ UHGXFHG FHOO GHDWK UHVSRQVH WR '1$ GDPDJH DQG FDWKHSVLQ PHGLDWHG DSRSWRVLV UHVSHFWLYHO\ (D) 08& OLNH RWKHU JO\FRSURWHLQV
XQGHUJRHVPXOWLSOHURXQGVRIVLDO\ODWLRQDQGJO\FRV\ODWLRQZKLOHFRQWLQXLQJRQWKHLWLQHUDU\WRWKH*ROJL08&DOVRKDVD&4&55.
VHTXHQFHPRWLIZKLFKXQGHUJRHVSDOPLWR\ODWLRQ7KHVHSRVWWUDQVODWLRQDOPRGL¿FDWLRQVDQGLQWHUDFWLQJSURWHLQSDUWQHUVSOD\LPSRUWDQW
roles in deciding the fate of MUC1.
www.impactjournals.com/oncotarget
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LQFUHDVHVWKHLQWHUDFWLRQEHWZHHQ08&DQGȕFDWHQLQ
and thus participates in MUC1-C translocation to the
F\WRVRO DQG QXFOHXV >@ 6R IDU WKH ROLJRPHUL]DWLRQ
of CQC sequence of MUC1-C has been shown to be
obligatory for MUC1-C nuclear translocation. The
translocation of the oligomerized MUC1-C into the
QXFOHXVLVIDFLOLWDWHGYLDLWVDVVRFLDWLRQZLWKLPSRUWLQȕ
and nucleoporin 62 [46], present on both the cytoplasmic
and nucleoplasmic sides of nuclear pore complex,
respectively. However, a recent report has indicated
that the ectodomain of MUC1 can also translocate to
the nucleus, although to different area of the nucleus.
MUC1-C localization to the nuclear periphery, nucleolar
and in nuclear matrix [47], whereas, the ectodomain of
08& RU 08&1 ORFDOL]HV WR WKH QXFOHDU VSHFNOHV
area which is primarily associated with the complex and
crucial process of splicing [48]. Intriguingly, MUC1
post-transcriptionally stabilizes galectin-3 expression in
breast cancer cells [49], which was attributed to MUC1
PHGLDWHG VXSSUHVVLRQ RI PLFUR51$ H[SUHVVLRQ
1HYHUWKHOHVV PL51$ LQGHSHQGHQW PHFKDQLVPV FRXOG
also be involved, as suggested by the presence of
08&1 LQ WKH QXFOHDU VSHFNOHV 7KHVH VWXGLHV PDNH
it evident for us to reconnoiter whether galectin-3
expression is regulated by the MUC1-N mediated
splicing process or not.
Altogether, growth factors induced nuclear
translocation of MUC1 in conjunction with other
RQFRJHQLF SURWHLQV VXFK DV ȖFDWHQLQ DQG ȕFDWHQLQ 
provides survival and proliferative advantages to the
cancer cells by inducing the transcription of other proteins
VXFK DV F\FOLQ' DQG FP\F LQ D 7&)/() IDPLO\
member-dependent transcriptional upregulation [50].

Lysosomal translocation of MUC1
5HFHQW UHSRUW KDV DOVR GHPRQVWUDWHG O\VRVRPH DV
another subcellular compartment where MUC1-C can
ORFDOL]H XWLOL]LQJ VLPLODU +63 GHSHQGHQW PHFKDQLVP
as used for mitochondrial localization (Fig. 2C) [53].
/RVVRI+63LVDVVRFLDWHGZLWKLQFUHDVHGLQWUDFHOOXODU
Ca2+ levels and lysosomal permeability, causing death
of pancreatic cancer cells [54]. However, the exact
PHFKDQLVPRIVXFK+63PHGLDWHGSURWHFWLRQZDVQRW
NQRZQ ,Q D UHFHQW VWXG\ %DQHUMHH et al. have shown
WKDW +63 SUHYHQWV O\VRVRPDO SHUPHDELOL]DWLRQ E\ LWV
physically interaction with MUC1-C. This association
is followed by the lysosomal translocation of MUC1-C
[53], which inhibits the release of lysosomal hydrolytic
HQ]\PHV SDUWLFXODUO\ FDWKHSVLQ % FDWKHSVLQ ' DQG
cathepsin L. These cathepsins can functions even at
a neutral cytosolic pH and have the ability to activate
apoptotic effectors such as calpains and caspases to
elicit apoptotic processes [55]. However, MUC1 overexpression followed by its cleavage to generate MUC1-C
is very well utilized by cancer cells to protect them from
harsh apoptotic programs.
Hence, altered localization of MUC1-C to the
lysosome followed by its interaction with overexpressed
O\VRVRPDO +63 LQ SDQFUHDWLF FDQFHU FHOOV SUHYHQWV
cathepsins mediated cell death response by inhibiting their
release from lysosome.

POST TRANSLATIONAL
MODIFICATION AND THE ABERRANT
LOCALIZATION OF MUC

Mitochondrial translocation of MUC1

Glycosylation

'HVSLWH WKH DEVHQFH RI D FODVVLFDO PLWRFKRQGULDO
localization signal, MUC1-C gets localized to the outer
membrane of mitochondria by its interaction with cytosolic
FKDSHURQHVVXFKDVWKH+63DQGWKH+63>@ Fig.
2B). MUC1-C mitochondrial localization has been
correlated with the diminished cell death response to
WKH'1$GDPDJHDQGRWKHUFHOOXODUVWUHVVE\LQKLELWLQJ
the release of cell-death causing factors. Cytosolic
sequestration of MUC1 exposes its hydrophobic TM
domains that facilitate their binding with chaperones, and
thus targeting to the mitochondria. Interestingly, Heregulin
+5*  D OLJDQG RI (*)5 IDPLO\ UHFHSWRU IDPLO\
HQKDQFHVWKHDVVRFLDWLRQEHWZHHQ08&&DQG+63
GXH WR DXWRSKRVSKRU\ODWLRQ DQG DFWLYDWLRQ RI F6UF LQ
HCT116/MUC1 cells [52] and facilitates the translocation
of MUC1-C to the mitochondria. In breast cancer cells,
FGF1 plays similar role in the mitochondrial localization
RI08&XVLQJVLPLODUPROHFXODUPHFKDQLVP>@7DNHQ
together, MUC1 translocation to the mitochondria might
be negatively regulating the programmed cell death.

$OOPXFLQVFRQWDLQ376GRPDLQVFRPSRVHGRISUROLQH
tyrosine and serine residues and serve as sites for extensive
2OLQNHG JO\FRV\ODWLRQ ZKLFK FRQWULEXWHV XS WR 
of their molecular weight and imparts most of their antigenic
epitopes [56]. Inhibition of O-glycosylation by 1-benzyl-2DFHWDPLGRGHR[\ĮGJDODFWRS\UDQRVLGH *DO1$FĮ2EQ 
impedes the apical targeting of glycoproteins by inhibiting
WKHGRFNLQJIXVLRQRISURWHLQFDUU\LQJYHVLFOHVWRWKHSODVPD
membrane, as this inhibitor interferes with the localization
RISURWHLQVLQYROYHGLQDSLFDOWUDI¿FNLQJVXFKDVWKHDSLFDO
W61$5(V\QWD[LQDQGWKHUDIWDVVRFLDWHGSURWHLQDQQH[LQ
XIIIb [57]. Besides O-glycosylation, MUC also contain
potential N-glycosylation sites. For example; MUC13
have seven N-glycosylation sites [58]. N-glycosylation of
MUC plays important roles in their folding, sorting, and
VHFUHWLRQ>@6WXGLHVKDYHGHPRQVWUDWHGWKDWDEVHQFHRI
1JO\FRV\ODWLRQEORFNVWKHDSLFDOWDUJHWLQJRIJO\FRSURWHLQV
which results in the accumulation of glycoproteins in the
*ROJL FRPSOH[ RI SRODUL]HG 0DGLQ'DUE\ FDQLQH NLGQH\
HSLWKHOLDOFHOOV 0'&. DQGQRQSRODUL]HG&KLQHVHKDPVWHU
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RYDU\ &+2 FHOOVDQGPDNHWKHPSURWHRO\WLFDOO\VHQVLWLYH
[60]. However, due to unresolved issues including that of
FHOO VSHFL¿FLW\ KDYH VR IDU SUHFOXGHG WKH LGHQWL¿FDWLRQ
RI VSHFL¿F JO\FDQ GHWHUPLQDQWV LQYROYHG LQ WKLV DSLFDO
targeting.
It has been observed that epithelial cancers expresses
MUC1 with truncated or under-glycosylated glycans,
VXFKDVWKH7Q *DO1$FĮ DQG7) *DOȕ*DO1$FĮ 
antigens [21]. Comparison of the stability of the
differentially glycosylated forms of MUC1, derived from
QRUPDO&+2FHOOVDQG8'3JOXFRVHHSLPHUDVHGH¿FLHQW
JO\FRV\ODWLRQGHIHFWLYH OGO'FHOOVUHYHDOHGWKDWGHIHFWLYH
JO\FRV\ODWLRQFDQVLJQL¿FDQWO\UHURXWH08&IURPWKH
plasma membrane to the degradation pathway. In a parallel
experiment, addition of exogenous GalNAc to the culture
media resulted in MUC1 stabilization on the cell surface
(60% of fully glycosylated MUC1), emphasizing the
importance of glycosylation in MUC stability. On the other
hand, MUC1 with short glycan structures have shown twofold higher rate of endocytosis via the hypertonic-media
sensitive clathrin-mediated pathway, along with increased
intracellular sequestration, as compared to the mature [356@
MUC1 [20, 21]. Interestingly, this increased internalization
of truncated MUC1 was not followed by its degradation.
Apart from clathrin-mediated endocytosis, a separate
study has shown that MUC1 can also be endocytosed
via macropinocytosis (Fig. 1) [22], which suggests the
involvement of multiple endocytic pathways in MUC1
internalization. These observations raise questions, such
DVZKHWKHUWKHDOWHUQDWLYHSDWKZD\RILQWHUQDOL]DWLRQLV
responsible for increased MUC1 endocytosis and does
the mode of internalization for MUC1 change during
pathological condition? Answer to these questions can
help us to design better strategies against MUC1 targeted
antigens.
)XUWKHU5D]DZLet al have suggested that membranelocalized and secretory MUC1, both have altered O-glycan
core structures, due to the differential pathway of their
WUDI¿FNLQJ >@ $XWKRUV XWLOL]HG UHFRPELQDQW HSLWRSH
tagged MUC1 (MUC1-M), mutants with defective
clathrin-mediated endocytosis (MUC1-M-Y20,60N) and
mutants with recycling defects (palmitoylation-defective
MUC1-M-CQC/AQA). Intriguingly, CQC/AQA mutants
VKRZHGVLJQL¿FDQWO\UHGXFHGOHYHORIWUDQVLWVWRWKH7*1
and accumulation in endosomal compartments. Analysis
of shed MUC1 ectodomain subunit of the CAC/AQA
mutant revealed change in the core glycan structures from
sialylated core 1 (MUC1-M, wild-type) to core 2 glycans
on the non-recycling CQC/AQA mutant. Interestingly, the
2JO\FRSUR¿OH RI WKH QRQUHF\FOLQJ &4&$4$ PXWDQW
H[KLELWVVLPLODULW\WRWKHFRUHJO\FRSUR¿OHRQDVHFUHWRU\
MUC1 which enters only once to the Golgi complex [61].
2QWKHRWKHUKDQG2JO\FRSUR¿OHRIWKH08&0<
60N mutant resembles the wild-type phenotype with
dominant core 1 expression.
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Sialylation
6LPLODUWRDOWHUHGJO\FRV\ODWLRQVLDO\ODWLRQSDWWHUQV
of MUC also differed in cancer cells as compared to the
normal healthy cells. Previous reports have demonstrated
the presence of immature form of episialin (MUC1) on
the cell surface under cancerous conditions. The immature
episialin is convertible to mature form by addition of sialic
residues through consecutive internalization and routing
of the MUC1 to the TGN (Fig. 2D) [62]. The half-life
of MUC1 at the plasma membrane has been calculated
WREH±K>@DQGHDFKURXQGRIVLDO\ODWLRQWDNHV
around 2.5 hours [62], which suggests that MUC1
possibly undergo recycling about 9–10 times. The multiple
rounds through TGN generate abnormally high levels of
sialylation [62], and have been correlated with increased
PHWDVWDWLF SRWHQWLDO RI FDQFHU FHOO >±@ 6LPLODUO\
HOHYDWHGVLDO\O/HZLV[ 6/H[ HSLWRSHKDVEHHQDVVRFLDWHG
with the poor prognosis of colon cancer patients [68]. In
DGGLWLRQGXHWRWKHSUHVHQFHRI6/H[HSLWRSHVRQVHOHFWLQ
ligands, the unusual higher levels of sialylation of MUC
could play a critical role in the invasion and metastasis
RIFDQFHUFHOOV>@DQGOHXNRF\WHH[WUDYDVDWLRQGXULQJ
LQÀDPPDWLRQ

Palmitoylation
08& KDV WKH &4&55. VHTXHQFH PRWLI ZKLFK
can be palmitoylated. This motif in MUC1 is present at
the boundary of TM domain and cytoplasmic tail, and its
palmitoylation has been correlated with MUC1 plasma
membrane retention. This MUC1 retention is achieved by
regulating MUC1 recycling at the apical surface without
interfering or altering the rate of its endocytosis [17].
6WXGLHV KDYH DOVR UHYHDOHG WKH LPSRUWDQFH RI W\URVLQH
residues at position 20 and 60 in the MUC1-CT domain,
in the process of endocytosis [70]. The Y20N mutation in
DVVRFLDWLRQZLWKWKH&4&55.PRWLILQKLELWWKHLQWHUDFWLRQ
of MUC1 with the adaptor proteins AP-1 and AP-2,
whereas the Y60N mutation inhibits MUC1 association
with another adaptor protein called Grb2. Transfection of
CHO cells with double mutant; AQA mutant and Y20N
PXWDQW FDXVHG 08& DFFXPXODWLRQ LQ 5DESRVLWLYH
UHF\FOLQJ HQGRVRPHV DSSDUHQWO\ GXH WR UHGXFHG DI¿QLW\
of the mutant for AP-1, and thus poor recycling. On the
other hand, transfection of Y20N mutant showed reduction
in the rate of endocytosis and internalization, however,
the subcellular distribution of MUC1 remain unchanged.
$OWRJHWKHUWKHVH¿QGLQJVVXJJHVWWKDWSDOPLWR\ODWLRQSOD\V
an important role in MUC1 routing from endosomes to the
plasma membrane. Palmitoylation of MUC1 cytoplasmic
tail might be inducing conformational changes which
could interfere with the interactions between MUC1CT and endocytosis regulating proteins. It is noteworthy
WKDW SDOPLWR\ODWLRQ LV DQ LPSRUWDQW PRGL¿FDWLRQ IRU WKH
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WUDI¿FNLQJ RI D QXPEHU RI UHFHSWRUV LRQ FKDQQHOV DQG
signaling proteins [71]. The precise mechanism by which
SDOPLWR\ODWLRQLVUHJXODWLQJPHPEUDQHWUDI¿FNLQJLVQRWDV
clear. The palmitoylation and depalmitoylation status permit
+5DVDQG*SURWHLQVXEXQLWVWRWUDQVGXFHVLJQDOVIURP
LQWUDFHOOXODUFRPSDUWPHQWVOLNH*ROJLFRPSOH[>@)URPD
clinical perspective, it may be worthwhile to design targeted
therapies against palmitoylation regulating enzymes.

The tradeoff between phosphorylation and
JO\FRV\ODWLRQ 2*OF1$F  LV NQRZQ WR UHJXODWH
LQWUDFHOOXODUWUDI¿FNLQJRI(*)5>@08&LVNQRZQ
WR LQWHUDFW ZLWK (*)5 DW SODVPD PHPEUDQH RI QRQ
polarized breast epithelia which resulted in increased
(*)5LQWHUQDOL]DWLRQUHGXFHGO\VRVRPDOGHJUDGDWLRQDQG
LQFUHDVHG(*)5UHF\FOLQJEDFNWRWKHSODVPDPHPEUDQH
>@ /LNHZLVH 08& KDV DOVR VKRZQ WR LQWHUDFW ZLWK
WKHRWKHU(*)5IDPLO\PHPEHU+(5YLDLWV(*)OLNH
motifs located at the juxtamembrane domains [82]. The
(*)OLNHPRWLILVDOVRSUHVHQWLQRWKHU08&OLNH08&
which has been implicated in the pathogenesis of colonic
LQÀDPPDWLRQ DQG FDQFHU DQG FDQ SUHVXPDEO\ LQLWLDWHV
(*)5 PHGLDWHG RQFRJHQLF VLJQDOLQJ ,QWHUHVWLQJO\
DFWLYDWHG(*)5SKRVSKRU\ODWHV<(.9PRWLILQ08&
&7WRLQGXFH08&LQWHUDFWLRQZLWKF6UFDQGȕFDWHQLQ
08&&7 DOVR KDV D ȖVHFUHWDVH FOHDYDJH PRWLI DQG
WKH FOHDYDJH E\ ȖVHFUHWDVH UHVXOWV LQ WKH UHOHDVH RI
intracellular MUC1-CT to regulate MUC1 mediated
cellular proliferation [83]. The MUC1-CT and E-cadherin
ERWK FRPSHWH IRU ȕFDWHQLQ ELQGLQJ GXH WR WKH ORVV RI
cellular polarity [45, 84].
/LNH(*)5IDPLO\PHPEHUVȕFDWHQLQDOVRUHVLGHV
at the lateral side of the cell. The loss of polarity allows
ȕFDWHQLQ WR LQWHUDFW ZLWK WKH 6$*1**66/ PRWLI
present in MUC1-C and the loss of E-cadherin-mediated
cell-to-cell interaction at MUC1 positive sites. Under
QRUPDO FRQGLWLRQV ȕFDWHQLQ LQWHUDFWV ZLWK WKH VLPLODU
6XXXXX66/PRWLIRI(FDGKHULQZKLFKLVUHTXLUHGIRU
the maintenance of the adherent junction. This interaction
EHWZHHQ ȕFDWHQLQ DQG 08& LV UHJXODWHG E\ (*)5
mediated phosphorylation of the crucial tyrosine residues
present on MUC1-CT [47]. Additionally, phosphorylation
RIWKHVHULQHUHVLGXHLQ63<(.9VHTXHQFHE\JO\FRJHQ
V\QWKDVHNLQDVHȕ *6.ȕ DVLWHDGMDFHQWWRWKHȕFDWHQLQ
binding motif inhibits the interaction between MUC1 and
ȕFDWHQLQ>@ZKHUHDVF6UFPHGLDWHGSKRVSKRU\ODWLRQRI
WKHW\URVLQHUHVLGXHLQWKDWVDPH63<(.9VLWHHQKDQFHV
WKHLULQWHUDFWLRQ>@08&VKRZVELQGLQJDI¿QLW\WRWKH
Armadillo repeats and the non-repetitive COOH-terminal
UHJLRQ RI ȕFDWHQLQ >@ 08& DQG ȕFDWHQLQ RQFH LQ
FRPSOH[PLWLJDWHV*6.ȕSKRVSKRU\ODWLRQRIȕFDWHQLQ
and translocate to the nucleus to transcriptionally activate
various genes implicated in increased carcinogenic
potential and metastasis [88]. In breast and colon cancers,
+5*VWLPXODWLRQIDFLOLWDWHVWKHELQGLQJEHWZHHQ08&
&7DQGȖFDWHQLQDOORZLQJ08&WRIXQFWLRQDVDYHKLFOH
IRU ȖFDWHQLQ QXFOHDU WUDQVORFDWLRQ >@ 7KHVH ¿QGLQJV
LQGLFDWHWKDW08&&'KDVFUXFLDOIXQFWLRQVLQLQWHJUDWLQJ
VLJQDOV IURP WKH (*)5 DQG :QW VLJQDOLQJ SDWKZD\V
8QOLNHLQ08&DQG08&WKH57.ELQGLQJPRWLILVQRW
present in MUC16-CT [89]. However, MUC16 secretion
LVLQÀXHQFHGE\(*)VWLPXODWLRQWKURXJKSKRVSKRU\ODWLRQ
RI 08&&7 >@ 08& NQRFNGRZQ LQ RYDULDQ
cancer cell lines caused increased cytoplasmic localization

DIFFERENTIAL INTERACTION OF
MUCINS WITH PROTEINS UNDER
PATHOLOGICAL CONDITION
Additional factors may also modulate the
localization of MUC under cancerous conditions. One
example is the differential MUC interactions due to
galectin-3 overexpression (Fig. 1) [73]. Galectin-3
is predominantly expressed as a cytosolic protein in
epithelial tissues, though it can also localize to the
nucleus, mitochondria and extracellular regions [74]. In
pancreatic cancer, silencing of galectin-3 has shown to
enhance the cell surface interaction between MUC1 and
(*)5 LQ WKH DEVHQFH RI (*) VWLPXODWLRQ DQG UHGXFHG
WKHUDWHRIHQGRF\WRVLVRI08&(*)5FRPSOH[ZKLFK
leads to the noticeable cell surface localization of MUC1.
However, presence of EGF stimulation leads to the nuclear
WUDQVORFDWLRQ RI (*)5 ZLWKRXW DIIHFWLQJ 08& FHOO
surface and MUC1-CT nuclear localization [75]. Upon
UHVFXLQJWKLVNQRFNGRZQHIIHFWE\UHFRPELQDQWJDOHFWLQ
discernible redistribution of MUC1 from the cell surface
to the cytoplasm was observed [75]. Therefore, galectin-3
overexpression in cancer could possibly be related to the
frequently observed intracellular retention of MUC1.

MODULATION OF SUB-CELLULAR
PROTEIN TRAFFICKING BY MUCINS
'XHWRWKHORVVRISRODULW\LQFDQFHU08& 08&
and MUC4) localize all over the cell surface, instead
RI UHVWULFWHG FRQ¿QHPHQW DW WKH DSLFDO VXUIDFH 7KLV
allows them to interact with cell surface proteins such
DV WKH (*)5 IDPLO\ PHPEHUV ZKLFK QRUPDOO\ H[LVW DW
the basolateral sides of polarized cells [76, 77]. MUC4
KDVVKRZQWRLQWHUDFWZLWK+(5(UE%LQRYDULDQDQG
pancreatic cancers [76, 78]. MUC4-ErbB2 complex lead
to the activation of various signaling pathways leading
to cell proliferation and survival through stimulation
RI S 0$3. SKRVSKRU\ODWLRQ >@ ,Q WKH DEVHQFH RI
the soluble ligand, the MUC4-ErbB2 complex leads
to ErbB2 phosphorylation, which in turn, leads to the
phosphorylation of the ErbB2-ErbB3 heterodimer in the
presence of neuregulin [80]. MUC4 did not demonstrate
interaction with ErbB3 in polarized cells, but loss of
polarity facilitates MUC4-ErbB3 interaction.
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RIȕFDWHQLQDQG(FDGKHULQDQGZDVOLQNHGZLWKJUHDWHU
cellular motility and invasiveness [89]. In agreement,
reduction of MUC16 expression has been related with
DGYDQFHG RYDULDQ FDQFHU >@ 7DNHQ WRJHWKHU WKHVH
studies pointed towards the possibility that the interactions
EHWZHHQ 08& (FDGKHULQ DQGRU ȕFDWHQLQ SHUPLW
MUC16 to modulate various signaling pathways.
Bitler et al. found evidence that MUC1 has
UHJXODWRU\ IXQFWLRQV LQ WKH WUDI¿FNLQJ DQG QXFOHDU
DFWLYLW\ RI (*)5 >@ 3UHVHQFH RI 08& VKRZHG
HQKDQFHLQWHUDFWLRQEHWZHHQ(*)5DQGSKRVSKRU\ODWHG
51$ SRO\PHUDVH ,, ZKLFK LPSOLHV WKDW 08& FDQ
LPSDFW WKH DVVRFLDWLRQ RI (*)5 ZLWK WUDQVFULSWLRQDO
machinery at the promoter region, as the loss of MUC1
UHGXFHVWKHRFFXSDQF\RI(*)5DWWKHF\FOLQ'SURPRWHU
region [47]. Besides controlling such inter-molecular
LQWHUDFWLRQV08&&DOVRUHJXODWHV5DEH[SUHVVLRQ
which is an early endosome protein belonging to the
VXEIDPLO\ RI VPDOO *73DVH 5DE >@ 08&& DQG
HVWURJHQUHFHSWRUIRUPDFRPSOH[DWWKH5DESURPRWHU
and are responsible for the transcriptional activation
RI 5DE $FFRUGLQJ WR WKLV VWXG\ SDWLHQWV ZKR
H[SUHVV08&&DQG5DEDUHUHVLVWDQWWRWDPR[LIHQ
treatment indicating the possible involvement of these
WZRPROHFXOHVLQGHWHUPLQLQJWKHHI¿FDF\RIWDPR[LIHQ
therapy [92].

PHGLDWRUV VXFK DV 5DE SURWHLQV 5DE KDV EHHQ VKRZQ
to participates in MUC1 internalization [22], and as
PHQWLRQHG SUHYLRXVO\ 5DE RYHUH[SUHVVLRQ LQGXFHV
08&& H[SUHVVLRQ >@ 5DE H[SUHVVLRQ SUR¿OHV DUH
modulated under different disease conditions, such as
5DE H[SUHVVLRQ LV DOWHUHG LQ EUHDVW DQG FRORUHFWDO
carcinomas [95, 96], and induce the invasive ability of
FDQFHUFHOOVE\LQWHUIHULQJZLWKWKHHQGRVRPDOWUDI¿FNLQJ
RI FHOO DGKHVLRQ SURWHLQV VXFK DV ȕLQWHUJULQV > @
6PDOOPROHFXODULQKLELWRUVWKDWWDUJHWSURPRWHUVRIWKHVH
5DE DQG RWKHU WUDI¿FNLQJ SURWHLQV FRXOG EH GHVLJQHG
to reroute MUC to the degradation pathways. Other
VPDOO PROHFXODU LQKLELWRUV OLNH JHOGDQDP\FLQ DQG
 DOO\ODPLQR GHPHWKR[\JHOGDQDP\FLQVLJQL¿FDQWO\
GLPLQLVKHG)*)LQGXFHG08&LQWHUDFWLRQZLWK+63
which as a consequence, obstructed MUC1 targeting to the
mitochondria [45].

MUC4 effects on HER2 internalization
08&VWDELOL]HV+(5RQWKHSODVPDPHPEUDQH
by inhibiting its internalization in pancreatic cancer
[76], whereas MUC1 induces the internalization of
(*)5 DQG GLUHFWV LW WR WKH QXFOHXV IRU WUDQVFULSWLRQDO
upregulation of oncogenic factors [47]. Presence
of MUC4 and MUC1-C has also been related with
Herceptin resistance in breast cancer [99, 100]. One of the
mechanism by which Herceptin functions is by binding
WR WKH H[WUDFHOOXODU GRPDLQ RI +(5 DQG LQGXFLQJ LWV
internalization for lysosomal mediated degradation [101].
7KHUHIRUHE\LQKLELWLQJ08&DQG+(5LQWHUDFWLRQE\
designing peptides against their interacting motifs could
LQFUHDVHWKHHI¿FDF\RI+HUFHSWLQWKHUDS\5HFHQWVWXG\
has shown that administration of GO-203 downregulates
the levels of phospho-p27 and cyclin-E, which abrogates
Herceptin resistance in breast cancer [102]. As MUC4
is one of the most differentially expressed proteins in
pancreatic cancer and has been associated with the
+HUFHSWLQUHVLVWDQFHLQEUHDVWFDQFHUWKHIDLOXUHRI+(5
trial in pancreatic cancer could possibly be attributed to
MUC4 aberrant overexpression, which requires further
investigation.

THERAPEUTIC PERSPECTIVES
The altered MUC localization and interactome
under pathological conditions provide new avenue
for the therapeutic intervention. Multiple studies have
investigated the potential of two well characterized MUCs,
MUC1 and MUC4, as therapeutic targets by restraining
their subcellular localization.

MUC1-C inhibitors
5HFHQWO\ SURWHLQWUDI¿FNLQJ SDWKZD\V KDYH EHHQ
exploited to enhance anti-cancer drug sensitivity of
melanoma cells. Melanoma cells showed 10-fold increase
LQWKHVHQVLWLYLW\WRFLVGLDPLQHGLFKORURSODWLQXP,, F''3
cis-platin), carboplatin and other anti-cancer drugs upon
depletion of the vacuolar protein sorting 33A or the
cappuccino protein [93], which strongly signpost the idea
WKDWWKHUDSHXWLFWDUJHWLQJRISURWHLQWUDI¿FNLQJPROHFXOHV
can increase the drug sensitivity of cancer cells.
GO-201 and GO-202 are two small peptides
that recognize the CQC motif in the amino terminal of
MUC1-C responsible for the translocation of MUC1-C
to various sub-cellular organelles [94]. Both GO-201
and GO-202 showed anti-tumorigenic functions in vitro
and in xenograft models [94]. Targeting the endocytic
YHVLFOHV WR FRPSDUWPHQW VSHFL¿F ORFDOL]DWLRQV FDQ DOVR
be accomplished by modulating the expression of critical

www.impactjournals.com/oncotarget

SUMMARY AND CONCLUSIONS
MUCs are the major macromolecular components
of epithelial mucus and have been incriminated in the
pathogenesis of various diseases. Their mislocalization
has been well associated with the pathobiology of several
cancers such as, breast and colorectal cancer. Under
normal condition, MUC are localized predominantly
on the apical surface, but loss of polarity allows them
to extend all over the cell surface and modulate their
LQWHUDFWRPH 6HYHUDO XQLTXH GRPDLQV SUHVHQW LQ 08&
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play crucial role in determining these interactions.
Mislocalization of MUC also facilitates MUC interactions
ZLWK RWKHU QRYHO SURWHLQV OLNH FDWHQLQ DQG WUDQVORFDWH
to different subcellular compartments. Though many
conjectures, including altered glycosylation, sialylation,
and differential protein-protein interactions, have been
made to answer altered localization of MUC, the exact
mechanism has not been explored and need immediate
attention for therapeutic interventions.
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